Cancer :: Methoxyamine – new cancer therapy reverses resistance to chemotherapy

Case Western Reserve University’s Technology Transfer Office has entered a worldwide exclusive licensing agreement with TRACON Pharmaceuticals of San Diego, Calif., to develop Methoxyamine, a new cancer therapeutic that reverses cancer cell resistance to chemotherapy. Methoxyamine is a “first in class” drug that targets a specific DNA repair pathway.

Allergy :: Food allergies could be fought with friendly bacteria in alcoholic milkshake

Feeding babies alcoholic milk may help to protect against some food allergies. Kefir, a traditional fermented drink, is consumed in Eastern Europe as a health food, and is often used to wean babies, as it is easily digested. Food allergy prevalence is especially high in children under the age of three, with around 5-8% of infants at risk. Currently the only treatment is avoidance of the problematic food.

Lung Cancer :: Key to lung cancer chemotherapy resistance revealed

Scientists at Johns Hopkins have discovered how taking the brakes off a ?detox? gene causes chemotherapy resistance in a common form of lung cancer. Products made by a gene called NRF2 normally protect cells from environmental pollutants like cigarette smoke and diesel exhaust by absorbing the materials and pumping them out of the cell. Another gene called KEAP1 encodes products that stop this cleansing process. But lung cancer cells sabotage the expression of these same genes to block assault from chemotherapy drugs.

Alzheimer’s Disease :: Antipsychotic Medications Used to Treat Alzheimer’s Patients Found Lacking

Commonly prescribed antipsychotic medications used to treat Alzheimer?s patients with delusions, aggression, hallucinations, and other similar symptoms can benefit some patients, but they appear to be no more effective than a placebo when adverse side effects are considered, according to the first phase of a large-scale clinical trial funded by the National Institutes of Health?s National Institute of Mental Health (NIMH). The trial, known as the Clinical Antipsychotic Trial of Intervention Effectiveness study for Alzheimer?s disease (CATIE-AD), was published in the October 12, 2006, issue of the New England Journal of Medicine.

Prostate Cancer :: Prostate Cancer Among African American Men

Bethesda, Md. ? Researchers from 12 institutions, including the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health (NIH), today announced the results of the first genome-wide linkage study of prostate cancer in African Americans. Using genetic markers, researchers identified several regions of the human genome that likely contain genes that, when altered, increase the risk of developing prostate cancer.

Allergy :: Experimental Ragweed Therapy Offers Allergy Sufferers Longer Relief with Fewer Shots

Americans accustomed to the seasonal misery of sneezing, runny noses and itchy, watery eyes caused by ragweed pollen might one day benefit from an experimental allergy treatment that not only requires fewer injections than standard immunotherapy, but leads to a marked reduction in symptoms that persists for at least a year after therapy has stopped, according to a new study in the October 5 issue of The New England Journal of Medicine (NEJM). The research was sponsored by the Immune Tolerance Network, which is funded by the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), both components of the National Institutes of Health (NIH), and the Juvenile Diabetes Research Foundation International.

Dementia :: Researchers Discover Misfolded Protein Clumps Common to Dementia, Lou Gehrig?s Disease

Scientists have identified a misfolded, or incorrectly formed, protein common to two devastating neurological diseases, frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig?s disease), according to a report in the Oct. 6, 2006, issue of Science. The findings suggest that certain forms of FTD, ALS and possibly other neurological diseases might share a common pathological process.

DNA :: NHGRI Aims to Make DNA Sequencing Faster, More Cost Effective

Bethesda, Md. ? The National Human Genome Research Institute (NHGRI), part of the National Institutes of Health (NIH), today announced the latest round of grant awards totaling more than $13.3 million to speed the development of innovative sequencing technologies that reduce the cost of DNA sequencing and expand the use of genomics in medical research and health care.

Dr. Anil Singhal Homeopathic Doctor | Dr. Anil Singhal's Blog | Manan - My Memoir by Dr. Anil Singhal | Boger's Legacy | Organon of Medicine | Health Newstrack